Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
CAMBRIDGE, Mass., Nov. 09, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present a company overview at the Jefferies 2017 London Healthcare Conference on Thursday, Nov. 16, 2017 at 11:20 a.m. GMT. The conference is being held Nov. 15-16, 2017 at the Waldorf Hilton, Aldwych, London.
To access the live webcast of Epizyme's presentation, please visit the Events & Presentations page within the Investor page of the website at www.epizyme.com. A replay of the webcast will be available on the Epizyme website for 60 days following the conference.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting cancer treatment through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. Using the Company's proprietary platform, Epizyme has pioneered the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, which can allow cancer cells to grow and proliferate. By focusing on the genetic drivers of cancers, Epizyme's science seeks to match targeted medicines with the specific patients that need it. For more information, visit www.epizyme.com.
Contacts:
Cheya Pope, Epizyme, Inc.
[email protected]
617-229-7561
Monique Allaire, THRUST IR
[email protected]
617-895-9511
